Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASi-KIDNEY
2024-511025-63-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing BI 690517 + empagliflozin with Placebo + empagliflozin (2 arms). Primary endpoint: Primary composite cardiorenal outcome. Planned start Oct 2024; status: authorised.
02
Drugs
vicadrostatempagliflozin
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2024-511025-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511025-63-00.